Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

BACKGROUND: Chronic kidney disease (CKD) is common and increasing in prevalence. Cardiovascular disease (CVD) is a major cause of morbidity and death in CKD, though of a different phenotype to the general CVD population. Few therapies have proved effective in modifying the increased CVD risk or rate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hill, Nathan R, Lasserson, Daniel, Thompson, Ben, Perera-Salazar, Rafael, Wolstenholme, Jane, Bower, Peter, Blakeman, Thomas, Fitzmaurice, David, Little, Paul, Feder, Gene, Qureshi, Nadeem, Taal, Maarten, Townend, Jonathan, Ferro, Charles, McManus, Richard, Hobbs, FD Richard
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4113231/
https://ncbi.nlm.nih.gov/pubmed/24886488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-15-160
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados